Pleural
Effectiveness of Surgical Treatment on Survival of Patients with Malignant Pleural Mesothelioma
Cancers 2025 July 16 [Link] Renata Báez-Saldaña, María Esther Marmolejo-Torres, Marco Antonio Iñiguez-García, Aída Jiménez-Corona, Juan Alberto Berrios-Mejía Abstract Background: The benefit of surgery for malignant pleural mesothelioma is highly debated, as few robust clinical trials show its effectiveness. Objective: To examine the long-term survival of patients with malignant pleural mesothelioma who underwent surgical treatment…
Read MoreTowards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
Critical Reviews in Oncology/Hematology 2025 July 23 [Link] Paolo Ambrosini, Alessia Stanzi, Giuseppe Lo Russo, Piergiorgio Solli, Mario Occhipinti Abstract Pleural mesothelioma is a rare malignancy that has historically had a poor prognosis, even with systemic chemotherapy. Although immune checkpoint inhibitors have improved survival rates for patients with advanced, unresectable disease, their role in perioperative…
Read MoreEnhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report
Molecular and Clinical Oncology 2025 July 3 [Link] Kazuki Yamada, Takehiro Uemura, Aya Mukai, Tatsuya Tanaka, Ippei Sakakibara, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Yutaka Ito, Tetsuya Oguri, Akio Niimi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer with limited treatment options and poor prognosis.…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim Kevin Blyth Paul White, Nick A Maskell 5, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim, Kevin Blyth, Paul White, Nick A Maskell, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified RECIST…
Read MoremicroRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma
Molecular Therapy, Nucleic Acids 2025 June 17 [Link] Nathanael Pruett, Sierra Wilferd, Anand Singh, Agnes Y Choi, Shivani Dixit, Vivek Singh, Charlize Nguyen, Olivia Lin, David S Schrump, Christopher L Plaisier, Chuong D Hoang Abstract Diffuse pleural mesothelioma (DPM) is an incurable surface neoplasm governed by tumor suppressor losses with limited therapeutic options. Despite the…
Read MoreThe Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Cancers 2025 June 25 [Link] Yuliya Semenova, Zhandos Burkitbayev, Nurtas Kalibekov, Alexandr Digay, Bakhyt Zhaxybayev, Oxana Shatkovskaya, Saule Khamzina, Dinara Zharlyganova, Zhuldyz Kuanysh, Almira Manatova Abstract Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural…
Read MoreMedical Thoracoscopy in Malignant Pleural Effusion
Cureus 2025 June 10 [Link] Amit K Rath, Sudarsan Pothal, Pallavi Bharadwaj Abstract Introduction: Malignant pleural effusion (MPE) is a common complication of advanced malignancies, often resulting in significant morbidity and impaired quality of life. In most cases, pleural fluid cytology remains negative. In the era of targeted cancer therapy, pathologists expect larger tissue samples.…
Read MorePrognostic Value of the HALP Score in Metastatic Mesothelioma: A Retrospective Study
Oncology 2025 July 8 [Link] Ozlem Dogan, Yakup Duzkopru, Tulay Eren Abstract Background: Malignant mesothelioma is a rare but aggressive cancer with limited treatment options and poor prognosis. Hemoglobin, Albumin, Lymphocyte, Platelet(HALP) score , reflecting inflammation and nutritional status, is a potential prognostic marker in various cancers. Our study aims to investigate the prognostic value…
Read MoreProlonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis
The Annals of Thoracic Surgery 2025 June 28 [Link] Peter L Zhan, Maureen E Canavan, Justin M Bader, Daniel J Boffa, Benjamin J Resio, Gavitt A Woodard Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS 2) trial demonstrated no survival benefit from cytoreductive surgical resection over chemotherapy alone in resectable pleural mesothelioma. Using the…
Read More